Product description

109889-09-0 - Properties

Trusted data

White or slightly yellowish white crystalline powder, odorless. Easily soluble in water, less soluble in methanol, extremely difficult to dissolve in ethanol, and almost insoluble in ether. Melting point is 290~292℃.

109889-09-0 - Preparation method

Trusted data

Granisetron is obtained by reacting l-methyl-1H-indazole-3-formyl chloride and 3-amino-9-methyl-9-azabicyclo[3.3.1]nonane. Acidify with hydrogen chloride-alcohol to obtain granisetron hydrochloride.

109889-09-0 - Purpose

Trusted data

Developed by Smithkline Beecham Company in the United States and launched in 1991. Granisetron is a potent and highly selective peripheral and central nervous system 5-HT3 receptor antagonist and one of the main anti-vomiting drugs. It has good preventive and therapeutic effects on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. It has a rapid onset of action and is better than ondansetron in controlling acute vomiting. For nausea and vomiting caused by cytotoxic drugs or radiation therapy.

Contact me

WhatsAPP: +8615383716096

Signal/Telegram:Helen SHDK

Wickr me:shanghaidekang

Email：helen@pharmsupplier.com

Main products

Company Profile